Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
Bremelanotide is a lab-made peptide that activates melanocortin receptors in the brain, a pathway tied to sexual arousal. This is a different mechanism from the tablets that work on blood flow. It is given as an under-the-skin injection or, in compounded forms, sometimes as a nasal spray.
It is the main peptide behind the brain-arousal angle that several sexual-wellness brands market. Because it works centrally, it draws interest from people for whom blood-flow tablets did not fit. Most peptide sellers reach buyers through content and email, not paid social ads.
| Claim | Strongest evidence |
|---|---|
| Sexual desire and arousal (approved women's use) | A Human RCT |
| Arousal support in men (off-label) | B Human open-label / small study |
| General libido enhancement | B Human open-label / small study |
Bremelanotide is FDA-approved as Vyleesi for one specific use: low sexual desire in premenopausal women. Any other use, and any compounded PT-141, is off-label and not FDA-approved. It requires a prescription from a licensed provider.
Sellers list PT-141 as a monthly plan. Several use a review-first model where you pay nothing until a provider approves, then a new authorization is required for each refill rather than an automatic charge. Observed pricing runs about 189 to 600 dollars a month.
| Where | Observed price | Model |
|---|---|---|
| PlexusDx (all-in monthly) | about $189 / month | No membership fee, cancel anytime, per-refill provider re-authorization |
| Typical clinic range (observed) | about $189 to $600 / month | Varies by dose, format (injection vs nasal), and provider |
Common reported effects include nausea, flushing, and injection-site reactions, plus temporary blood-pressure changes noted in the approved label. Compounded PT-141 is not FDA-reviewed for quality or for uses beyond the approved women's indication. A licensed provider should screen for blood-pressure and heart risk.
Direct-to-consumer clinics list it around 189 to 600 dollars a month. One all-in plan is about 189 dollars a month with no membership fee and a fresh provider approval for each refill.
The tablets work mainly on blood flow. Bremelanotide works on arousal pathways in the brain, a central mechanism, which is why it interests people the tablets did not fit.
One form, Vyleesi, is FDA-approved for low sexual desire in premenopausal women. Other uses and compounded PT-141 are off-label and not FDA-approved.
One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.